[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632727":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":42,"centralContacts":46,"locations":53,"responsibleParty":131,"collaborators":133,"id":137,"slug":28,"hasResults":138,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":28,"eligibilityCriteria":142,"healthyVolunteers":138,"sex":143,"minAge":144,"maxAge":145,"enrollmentInfo":146,"targetDuration":28,"studyType":149,"phases":150,"briefSummary":152,"conditions":153,"keywords":155,"overallStatus":56,"whyStopped":28,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":170},{"fullName":5,"class":6},"Gates Medical Research Institute","OTHER",[8,15,18],{"label":9,"type":10,"description":11,"interventionNames":12},"BPAL\u002FNAM1500","EXPERIMENTAL","Nicotinamide, bedaquiline, pretomanid, linezolid",[13,14],"Drug: Bedaquiline, pretomanid, linezolid","Dietary Supplement: Nicotinamide (NAM)",{"label":16,"type":10,"description":11,"interventionNames":17},"BPAL\u002FNAM2500",[13,14],{"label":19,"type":20,"description":21,"interventionNames":22},"BPAL","ACTIVE_COMPARATOR","Bedaquiline, pretomanid, linezolid",[13],[24,29,32,35],{"type":25,"name":21,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","Group 1 (Approximately 55 participants), Combination of NAM 1500 mg twice daily (BID) with bedaquiline (200 mg once daily \\[QD\\]), pretomanid (200 mg QD), and linezolid (600 mg QD), 56 days",[9],null,{"type":25,"name":21,"description":30,"armGroupLabels":31,"otherNames":28},"Group 2 (Approximately 55 participants): Combination of NAM 2500 mg BID with bedaquiline (200 mg QD), pretomanid (200 mg QD), and linezolid (600 mg QD), 56 days",[16],{"type":25,"name":21,"description":33,"armGroupLabels":34,"otherNames":28},"Group 3 (active control; approximately 55 participants): Combination of bedaquiline (200 mg QD), pretomanid (200 mg QD), and linezolid (600 mg QD), 56 days",[19],{"type":36,"name":37,"description":38,"armGroupLabels":39,"otherNames":40},"DIETARY_SUPPLEMENT","Nicotinamide (NAM)","Group 1 (Approximately 55 participants), Combination of NAM 2500 mg twice daily (BID) with bedaquiline (200 mg once daily \\[QD\\]), pretomanid (200 mg QD), and linezolid (600 mg QD), 56 days",[9,16],[41],"Nicotinamide also abbreviated as NAM and also known as niacinamide .",[43],{"name":44,"affiliation":5,"role":45},"Gates MRI","STUDY_DIRECTOR",[47,51],{"name":44,"role":48,"phone":49,"phoneExt":28,"email":50},"CONTACT","+857-702-2108","Clinical.trials@gatesmri.org",{"name":44,"role":48,"phone":52,"phoneExt":28,"email":50},"+1-866-789-5757",[54,78,97,116],{"facility":55,"status":56,"city":57,"state":58,"zip":59,"country":60,"cosmosGeoPoint":61,"geoPoint":66,"contacts":67},"Wits RHI - Shandukani Research","RECRUITING","Johannesburg","Gauteng","2001","South Africa",{"type":62,"coordinates":63},"Point",[64,65],28.04363,-26.20227,{"lat":65,"lon":64},[68,72,76],{"name":69,"role":48,"phone":70,"phoneExt":28,"email":71},"Nkosiphile Ndlovu, MD","011 358 5300","nkndlovu@wrhi.ac.za",{"name":73,"role":48,"phone":74,"phoneExt":28,"email":75},"Zikhona Njengele Tetyana","083 3642","znjengele-tetyana@wrhi.ac.za",{"name":69,"role":77,"phone":28,"phoneExt":28,"email":28},"PRINCIPAL_INVESTIGATOR",{"facility":79,"status":56,"city":80,"state":58,"zip":81,"country":60,"cosmosGeoPoint":82,"geoPoint":86,"contacts":87},"The Aurum Institute Clinical Research Site - Pretoria","Pretoria","87",{"type":62,"coordinates":83},[84,85],28.18783,-25.74486,{"lat":85,"lon":84},[88,92,96],{"name":89,"role":48,"phone":90,"phoneExt":28,"email":91},"Vaneshree Govender, MD","012 844 0145","vgovender@auruminstitute.org",{"name":93,"role":48,"phone":94,"phoneExt":28,"email":95},"Innocent Shibambo","082 495 9556","ishibambo@auruminstitute.org",{"name":89,"role":77,"phone":28,"phoneExt":28,"email":28},{"facility":98,"status":56,"city":99,"state":100,"zip":101,"country":60,"cosmosGeoPoint":102,"geoPoint":106,"contacts":107},"TASK Clinical Research Centre","Cape Town","Western Cape","7530",{"type":62,"coordinates":103},[104,105],18.42322,-33.92584,{"lat":105,"lon":104},[108,112,115],{"name":109,"role":48,"phone":110,"phoneExt":28,"email":111},"Andrew Parker, MD","021 9171044","dr.andrew@task.org.za",{"name":113,"role":48,"phone":110,"phoneExt":28,"email":114},"Lukhanyile Ketelo","l.ketelo@taskclinical.com",{"name":109,"role":77,"phone":28,"phoneExt":28,"email":28},{"facility":117,"status":56,"city":99,"state":100,"zip":118,"country":60,"cosmosGeoPoint":119,"geoPoint":121,"contacts":122},"Centre of Tuberculosis Research Innovation","7700",{"type":62,"coordinates":120},[104,105],{"lat":105,"lon":104},[123,127,130],{"name":124,"role":48,"phone":125,"phoneExt":28,"email":126},"Rodney Dawson, MD","021 406 6850","rodney.dawson@uct.ac.za",{"name":128,"role":48,"phone":28,"phoneExt":125,"email":129},"Shanel Linde","shanel.linde@uct.ac.za",{"name":124,"role":77,"phone":28,"phoneExt":28,"email":28},{"type":132,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR",[134],{"name":135,"class":136},"IQVIA RDS Inc.","INDUSTRY","100632727",false,"NCT07517445","Bactericidal Activity and Safety of Nicotinamide in Combination With Bedaquiline, Pretomanid, and Linezolid in Drug-susceptible Pulmonary Tuberculosis","A Phase 2, Open-label, Randomized Controlled Trial to Assess the Safety, Bactericidal Activity, and Pharmacokinetics of Nicotinamide in Combination With Bedaquiline, Pretomanid, and Linezolid in Adults With Drug-susceptible Pulmonary Tuberculosis","Inclusion Criteria:\n\n* Age 18-65 years at consent\n* Body weight 40-100 kg at screening\n* Written informed consent obtained\n* Newly diagnosed pulmonary TB, rifampicin- and isoniazid-sensitive\n\n  * ≥1+ AFB smear OR positive Xpert semi-quantitative result\n  * Molecular confirmation of M. tuberculosis\n* Chest X-ray consistent with TB (Investigator assessment)\n* Able to spontaneously produce sputum\n* Contraception requirements met\n* Females Of Child Bearing Potential: 2 approved contraceptive methods or abstinence\n* Males: contraception or abstinence through 90 days post-dose\n\nExclusion Criteria:\n\n* Prior TB within 3 years, \\>1 prior episode, or anti-TB treatment within 60 days\n* Extrapulmonary TB (except non-significant pleural\u002Flymph node disease)\n* Clinically significant comorbidities or substance abuse impacting safety\u002Fcompliance\n* Pregnant or breastfeeding\n* HIV-positive AND any of the following:\n* Not on ART or on ART \\\u003C3 months\n* CD4 \\\u003C200 cells\u002FµL\n* Viral load \\>200 copies\u002FmL\n* AIDS-defining illness (other than pulmonary TB)\n* Screening lab abnormalities (protocol-defined LFTs, hematology, hepatitis B or C, HbA1c)\n* Clinically significant ECG abnormality\n* Use of prohibited concomitant medications (e.g., strong CYP3A4 modifiers, certain SSRIs)","ALL","18 Years","65 Years",{"count":147,"type":148},165,"ESTIMATED","INTERVENTIONAL",[151],"PHASE2","The purpose of this study is to determine if nicotinamide in combination with bedaquiline, pretomanid, and linezolid, is safe and effective in treating drug-susceptible pulmonary tuberculosis.",[154],"Drug Susceptible Pulmonary Tuberculosis",[156,157,158,159,160],"Nicotinamide","bedaquiline","pretomanid","linezolid","drug-susceptible pulmonary tuberculosis","2026-06-30",{"date":163,"type":164},"2026-07-02","ACTUAL",{"date":166,"type":164},"2026-04-17",{"date":168,"type":148},"2027-06-14",{"name":5,"class":6},4]